Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters








Language
Year range
1.
Article in Chinese | WPRIM | ID: wpr-1046005

ABSTRACT

Objective: To evaluate the immunogenicity, safety, and immune persistence of the sequential booster with the recombinant protein-based COVID-19 vaccine (CHO cell) in healthy people aged 18-84 years. Methods: An open-label, multi-center trial was conducted in October 2021. The eligible healthy individuals, aged 18-84 years who had completed primary immunization with the inactivated COVID-19 vaccine 3 to 9 months before, were recruited from Shangyu district of Shaoxing and Kaihua county of Quzhou, Zhejiang province. All participants were divided into three groups based on the differences in prime-boost intervals: Group A (3-4 months), Group B (5-6 months) and Group C (7-9 months), with 320 persons per group. All participants received the recombinant COVID-19 vaccine (CHO cell). Blood samples were collected before the vaccination and after receiving the booster at 14 days, 30 days, and 180 days for analysis of GMTs, antibody positivity rates, and seroconversion rates. All adverse events were collected within one month and serious adverse events were collected within six months. The incidences of adverse reactions were analyzed after the booster. Results: The age of 960 participants was (52.3±11.5) years old, and 47.4% were males (455). The GMTs of Groups B and C were 65.26 (54.51-78.12) and 60.97 (50.61-73.45) at 14 days after the booster, both higher than Group A's 44.79 (36.94-54.30) (P value<0.05). The GMTs of Groups B and C were 23.95 (20.18-28.42) and 27.98 (23.45-33.39) at 30 days after the booster, both higher than Group A's 15.71 (13.24-18.63) (P value <0.05). At 14 days after the booster, the antibody positivity rates in Groups A, B, and C were 91.69% (276/301), 94.38% (302/320), and 93.95% (295/314), respectively. The seroconversion rates in the three groups were 90.37% (272/301), 93.75% (300/320), and 93.31% (293/314), respectively. There was no significant difference among these rates in the three groups (all P values >0.05). At 30 days after the booster, antibody positivity rates in Groups A, B, and C were 79.60% (238/299), 87.74% (279/318), and 90.48% (285/315), respectively. The seroconversion rates in the three groups were 76.92% (230/299), 85.85% (273/318), and 88.25% (278/315), respectively. There was a significant difference among these rates in the three groups (all P values <0.001). During the sequential booster immunization, the incidence of adverse events in 960 participants was 15.31% (147/960), with rates of about 14.38% (46/320), 17.50% (56/320), and 14.06% (45/320) in Groups A, B, and C, respectively. The incidence of adverse reactions was 8.02% (77/960), with rates of about 7.50% (24/320), 6.88% (22/320), and 9.69% (31/320) in Groups A, B, and C, respectively. No serious adverse events related to the booster were reported. Conclusion: Healthy individuals aged 18-84 years, who had completed primary immunization with the inactivated COVID-19 vaccine 3 to 9 months before, have good immunogenicity and safety profiles following the sequential booster with the recombinant COVID-19 vaccine (CHO cell).


Subject(s)
Male , Cricetinae , Animals , Humans , Adult , Middle Aged , Female , COVID-19 Vaccines , Immunization, Secondary , CHO Cells , COVID-19/prevention & control , Recombinant Proteins , Antibodies, Viral , Antibodies, Neutralizing
2.
Article in Chinese | WPRIM | ID: wpr-1046328

ABSTRACT

Objective: To evaluate the immunogenicity, safety, and immune persistence of the sequential booster with the recombinant protein-based COVID-19 vaccine (CHO cell) in healthy people aged 18-84 years. Methods: An open-label, multi-center trial was conducted in October 2021. The eligible healthy individuals, aged 18-84 years who had completed primary immunization with the inactivated COVID-19 vaccine 3 to 9 months before, were recruited from Shangyu district of Shaoxing and Kaihua county of Quzhou, Zhejiang province. All participants were divided into three groups based on the differences in prime-boost intervals: Group A (3-4 months), Group B (5-6 months) and Group C (7-9 months), with 320 persons per group. All participants received the recombinant COVID-19 vaccine (CHO cell). Blood samples were collected before the vaccination and after receiving the booster at 14 days, 30 days, and 180 days for analysis of GMTs, antibody positivity rates, and seroconversion rates. All adverse events were collected within one month and serious adverse events were collected within six months. The incidences of adverse reactions were analyzed after the booster. Results: The age of 960 participants was (52.3±11.5) years old, and 47.4% were males (455). The GMTs of Groups B and C were 65.26 (54.51-78.12) and 60.97 (50.61-73.45) at 14 days after the booster, both higher than Group A's 44.79 (36.94-54.30) (P value<0.05). The GMTs of Groups B and C were 23.95 (20.18-28.42) and 27.98 (23.45-33.39) at 30 days after the booster, both higher than Group A's 15.71 (13.24-18.63) (P value <0.05). At 14 days after the booster, the antibody positivity rates in Groups A, B, and C were 91.69% (276/301), 94.38% (302/320), and 93.95% (295/314), respectively. The seroconversion rates in the three groups were 90.37% (272/301), 93.75% (300/320), and 93.31% (293/314), respectively. There was no significant difference among these rates in the three groups (all P values >0.05). At 30 days after the booster, antibody positivity rates in Groups A, B, and C were 79.60% (238/299), 87.74% (279/318), and 90.48% (285/315), respectively. The seroconversion rates in the three groups were 76.92% (230/299), 85.85% (273/318), and 88.25% (278/315), respectively. There was a significant difference among these rates in the three groups (all P values <0.001). During the sequential booster immunization, the incidence of adverse events in 960 participants was 15.31% (147/960), with rates of about 14.38% (46/320), 17.50% (56/320), and 14.06% (45/320) in Groups A, B, and C, respectively. The incidence of adverse reactions was 8.02% (77/960), with rates of about 7.50% (24/320), 6.88% (22/320), and 9.69% (31/320) in Groups A, B, and C, respectively. No serious adverse events related to the booster were reported. Conclusion: Healthy individuals aged 18-84 years, who had completed primary immunization with the inactivated COVID-19 vaccine 3 to 9 months before, have good immunogenicity and safety profiles following the sequential booster with the recombinant COVID-19 vaccine (CHO cell).


Subject(s)
Male , Cricetinae , Animals , Humans , Adult , Middle Aged , Female , COVID-19 Vaccines , Immunization, Secondary , CHO Cells , COVID-19/prevention & control , Recombinant Proteins , Antibodies, Viral , Antibodies, Neutralizing
3.
Zhongguo yi xue ke xue yuan xue bao ; Zhongguo yi xue ke xue yuan xue bao;(6): 92-100, 2023.
Article in Chinese | WPRIM | ID: wpr-970452

ABSTRACT

Laminin subunit alpha 4 (LAMA4),a member of the laminin family,is present in the intercellular matrix of adult tissues as a major component of basement membrane.LAMA4 is involved in the adhesion of cells and can bind to corresponding integrins to activate relevant signaling pathways,playing an essential role in the growth,proliferation,and migration of cells.It has been demonstrated that LAMA4 is associated with the occurrence and development of a variety of diseases including tumors,and the expression of LAMA4 can be used as a biomarker of tumor diagnosis and prognosis.This paper summarizes the current research progress in LAMA4 with the focus on the relationship between LAMA4 and diseases,especially tumor,with a view to provide new directions for the future research.


Subject(s)
Adult , Humans , Laminin , Extracellular Matrix
4.
Chinese Pharmaceutical Journal ; (24): 679-683, 2012.
Article in Chinese | WPRIM | ID: wpr-860739

ABSTRACT

OBJECTIVE: To detect the levels of aquaglyceroporin 9 (AQP9) mRNA expression, AQP9 and p38 proteins and their phosphorylation in HepG2 and L-02 cells treated with NaAsO2, and to investigate the association of these expression levels with arsenic intake and the AQP9 phosphorylation mechanism. METHODS: The intracellular arsenic content was determined by inductively coupled plasma mass spectrometry (ICP-MS). Real-time quantitative PCR, Western blotting and immunoprecipitation techniques were used to detect AQP9 mRNA, AQP9 and p38 protein levels and their phosphorylation levels in HepG2 and L-02 cells. SPSS statistical software was used to analyze experimental data. RESULTS: Intracellular arsenic content and intake rate in HepG2 cells were faster than those in L-02 cells. AQP9 mRNA levels in L-02 cells was increased with time within 6 h after NaAsO2 treatment (P<0.05), while no significant change was observed in L-02 cells. Two hours after treatment, AQP9 gene levels in HepG2 cells were all significantly increased at different concentrations of NaAs02. The phosphorylation levels of AQP9 in HepG2 cells were increased with treating time and concentration of NaAsO2. While the phosphorylation levels of AQP9 in L-02 cells significantly increased compared to control at each time point and concentration, but no significant difference was shown between the treatments. p38 phosphorylation levels in both cells were increased with time. Inhibition of p38 activity by SB203580 completely abolished AQP9 protein phosphorylation in L-02 cells, while it had no significant effect on HepG2 cells. CONCLUSION: AQP9 expression and phosphorylation levels may play an important role in regulating arsenic influx; regulation mechanism of AQP9 phosphorylation may be different in different cells. Copyright 2012 by the Chinese Pharmaceutical Association.

SELECTION OF CITATIONS
SEARCH DETAIL